Entasis Therapeutics Holdings Inc

Entasis Therapeutics Holdings, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery and development of novel antibacterial products for serious drug-resistant bacterial infections. Its anti-infective discovery platform has produced a pipeline of differentiated programs, which is bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), Non-Beta-lactam PBP inhibitor, and Zoliflodacin. The company was founded in May 2015 and is headquartered in Waltham, MA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

WALTHAM, Mass., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced today that management will participate in the upcoming Cantor Fitzgerald Virtual Global Healthcare Conference to be held September 27-30, 2021.

Entasis Therapeutics to Participate in the Cantor Fitzgerald Virtual Global Healthcare Conference

Leap Therapeutics

Reed's

Trading penny stocks in a down market? Here's three tips and tricks to use in your search The post Making Money With Penny Stocks During a Stock Market Crash appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Making Money With Penny Stocks During a Stock Market Crash

Entasis Therapeutics Holdings Inc (NASDAQ: ETTX) stock is up sharply after the journal Nature published an article on the potential of its preclinical candidate ETX0462, which could become the first of a new class of antibiotics. ETX0462 is under development for multidrug-resistant Gram-negative and biothreat infections.

Why Are Entasis Therapeutics Shares Moving Higher On Thursday?

Publication Details the Discovery and Preclinical Profile of ETX0462, a First-in-Class Candidate Against Multidrug-Resistant Pathogens Publication Details the Discovery and Preclinical Profile of ETX0462, a First-in-Class Candidate Against Multidrug-Resistant Pathogens

Profile of Entasis Therapeutics ETX0462 Candidate Published in the Journal Nature

Entasis Therapeutics Holdings Inc. (ETTX) CEO Manoussos Perros on Q2 2021 Results - Earnings Call Transcript

-Management to Host Conference Call on August 12 at 8am ET-

Entasis Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update

– Virtual Event to be Held Tuesday, August 24 at 10am Eastern Time –

Entasis Therapeutics to Host Expert Perspectives Webinar on Acinetobacter Infections

WALTHAM, Mass., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced members of management will participate in the Wedbush PacGrow Healthcare Conference, to be held virtually from August 10-11, 2021.

Entasis Therapeutics to Participate in the 2021 Wedbush PacGrow Healthcare Conference

– Significant commercial strategy and product launch experience – – ATTACK Phase 3 top-line data readout remains on-track for 2H 2021 –

Entasis Therapeutics Expands Executive Leadership Team with the Appointment of Anna Diaz Triola as Chief Commercial Officer

WALTHAM, Mass., July 01, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced the presentation of preclinical data on ETX0462, a novel, first-in-class, diazabicyclooctane with antimicrobial activity against multidrug-resistant (MDR) Gram-negative and biothreat pathogens, at the 2021 World Microbe Forum. ETX0462 potentially represents the first new antibiotic class in 35 years to treat MDR Gram-negative and biothreat infections.

Entasis Therapeutics Introduces ETX0462, a First-in-Class Candidate, Targeting Multidrug-Resistant Gram-Negative and Biothreat Pathogens

WALTHAM, Mass., June 18, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced multiple presentations at the World Microbe Forum 2021, taking place virtually June 20-24. Entasis will present 11 posters with one oral presentation highlighting ETX0462, a novel, first-in-class, diazabicyclooctane with antimicrobial activity against Pseudomonas aeruginosa. Presentations will also include updates on SUL-DUR, a β-lactam/β-lactamase inhibitor currently in a Phase 3 registrational clinical trial to treat infections caused by carbapenem-resistant Acinetobacter baumannii, and ETX0282CPDP, an oral β-lactam/β-lactamase inhibitor being developed to treat multidrug-resistant Gram-negative pathogens, including those caused by extended-spectrum β-lactamases (ESBLs) and carbapenem-resistant Enterobacteriaceae (CRE).

Entasis Therapeutics Introduces First-in-Class Candidate, ETX0462, and Presents Data on SUL-DUR and ETX0282CPDP at World Microbe Forum

Ault Global Holdings

Evofem Biosciences Inc

OpGen

Precipio

Penny stocks to watch right now after insiders bought in June. The post 5 Top Penny Stocks Insiders Decided To Buy In June 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

5 Top Penny Stocks Insiders Decided To Buy In June 2021

The stock price of Entasis Therapeutics Holdings Inc (NASDAQ: ETTX) increased by over 50% pre-market. These are the details.

ETTX Stock Price: Over 40% Increase Pre-Market Details

– ATTACK Phase 3 topline data readout remains on track for second half of 2021 –             – Strengthened balance sheet with $20M financing –

Entasis Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update

WALTHAM, Mass., May 03, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced today that it has completed the initial closing of an approximately $7.5 million stock and warrant issuance to a subsidiary of Innoviva Inc. (Nasdaq: INVA) ("Innoviva"), pursuant to a securities purchase agreement signed on May 3, 2021. Upon satisfaction of certain closing conditions, including approval by Entasis stockholders, Innoviva will purchase the balance of the $20 million in Entasis common stock and warrant securities in a second closing that is anticipated later in the second quarter of 2021 (excluding the consideration payable upon exercise of warrants, if any).

Entasis Therapeutics Completes Initial Closing of $20M Private Placement with Innoviva

– Phase 3 ATTACK registration trial more than three-quarters complete – – ATTACK topline data readout expected second half of 2021 – – Zoliflodacin Phase 3 trial adds clinical trial sites, continues enrollment –

Entasis Therapeutics Reports Full Year 2020 Financial Results and Provides Business Update

WALTHAM, Mass., Jan. 26, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced today the availability of an expanded access program (EAP) for sulbactam-durlobactam or SUL-DUR, an investigational drug, for U.S. patients with Acinetobacter baumannii infections, including carbapenem and multidrug resistant strains.

Entasis Therapeutics Announces Sulbactam-Durlobactam Expanded Access Program for Patients in the U.S.

WALTHAM, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that Dr. Manos Perros, President and Chief Executive Officer of the Company, will present at the virtual H.C. Wainwright BioConnect 2021 Conference being held January 11-14, 2021.

Entasis Therapeutics to Present at the H.C. Wainwright BioConnect 2021 Conference

WALTHAM, Mass., Nov. 17, 2020 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that members of management will participate in A.G.P.'s Virtual Healthcare Symposium on Thursday, November 19th, 2020.

Entasis Therapeutics to Participate in A.G.P.'s Virtual Healthcare Symposium

WALTHAM, Mass., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced today its third quarter 2020 financial results and provided a business update.

Entasis Therapeutics Reports Third Quarter 2020 Financial Results and Provides a Business Update

WALTHAM, Mass., Oct. 14, 2020 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced the company will have multiple data presentations at the virtual ID Week, being held October 21-25, 2020.

Entasis Therapeutics Highlights Multiple Data Presentations at Virtual ID Week

WALTHAM, Mass., Sept.  10, 2020  (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that Dr. Manos Perros, President and Chief Executive Officer of the Company, will present virtually at the H.C. Wainwright & Co. 22nd Annual Global Investment Conference on September 15th, the Cantor 2020 Virtual Global Healthcare Conference on September 17th, and the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 22nd.

Entasis Therapeutics to Participate in Upcoming Healthcare Investor Conferences

Proceeds to support the ongoing ATTACK Phase 3 registration clinical trial Proceeds to support the ongoing ATTACK Phase 3 registration clinical trial

Entasis Therapeutics Announces $25 Million Private Placement

WALTHAM, Mass., Aug.  05, 2020  (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that Dr. Manos Perros, President and Chief Executive Officer of the Company, will present virtually at the 2020 Wedbush PacGrow Healthcare Virtual Conference on Tuesday, August 11th at 11:30am ET and at the Canaccord Genuity 40th Annual Growth Conference on Wednesday, August 12th at 9:00am ET.

Entasis Therapeutics to Participate in Upcoming Healthcare Conferences

Entasis Therapeutics (ETTX) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

News for Entasis Therapeutics Holdings Inc Stock (ETTX)